| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d4274a49221d3e597ac062549fc10a59
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_31fb964e2148aff14f5bfc5f5ae6fbaf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f5ed86c54dff5c7810662faee512bc85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_116c12ee4fc8da59d5bdb32af27f2f9d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3c41f52449fb5ebc69f231ab4537b690 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1275
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-685 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 |
| filingDate |
2011-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d75b0ba24c953d606ecd74036dc913a1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be5e4198c0d239f4bc4b6ea9285f34ef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5496577f7d5d3b236b2361344715255
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_133e2503e015fdf8db3f720292344ccb |
| publicationDate |
2013-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2013190226-A1 |
| titleOfInvention |
Reconstituted high density lipoprotein formulation and production method thereof |
| abstract |
A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015173633-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018015171-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11129900-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101563403-B1 |
| priorityDate |
2010-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |